Triera Biosciences

Triera Biosciences Logo

Why Invest in Triera Biosciences?

Be Part of a Rising Wave

Triera Biosciences is where groundbreaking innovation meets the future of healthcare. We invite you to embark on a journey that has the potential to transform millions of lives.

Aptamers are perfectly poised to improve lives around the world, targeting diseases with unmet medical needs such as viruses, cancers, neurodegenerative disorders, and rare genetic conditions.

Discovery Pipeline
Primary Target
Respiratory Infectious Diseases (inc. COVID-19)
Additional Target #1
Infectious Diseases
Additional Target #2
Current Monoclonal Antibody Targets
Additional Target #3
Oncological Targets
Additional Target #4
Other Innovative and Challenging Targets

Our current primary focus is on the treatment of respiratory infectious diseases such as COVID-19 and influenza, but the potential of aptamers opens the door to the possibility of targeting infectious diseases, current monoclonal antibody targets, oncological targets, and other innovative and challenging targets in the near future.

Validation and current research and accelerated pre-clinical trials are the focus of initial planning and effort. Platform establishment and a long-term research and commercialization plan are being developed in conjunction with research efforts.

Solving Global Challenges

Aptamers can target a wide range of diseases that affect communities worldwide, including RSV, tuberculosis, influenza, and SARS-CoV-2 variants including COVID-19.

RSV

US Outpatient Visits
(2015-22)
0 M

Tuberculosis

Global Infections
(2019)
0 M

Influenza

US Medical Visits
(2019-20)
1 M

SARS-CoV-2
(inc. COVID-19)

Global Infections
(2019-23)*
1 M+

Combined Total Deaths

Worldwide
(2015-23)
~ 0 M

*statista.com – “Number of Coronavirus (COVID-19) Cases Worldwide as of May 2, 2023, by Country or Territory” [August 29, 2023]

Disrupting the Expanding Antibody Market

The current global antibody market is based around monoclonal antibodies. This branch of medicine was developed in the 1980s. COVID-19 revealed the pressing need for a faster, more effective, more adaptable, and cost-efficient solution. Aptamer-based therapeutical platforms are a modern alternative to developing vaccines and other precision medicines. Triera Biosciences is at the forefront of this field – a field with the proven potential to surpass monoclonal antibodies on virtually every front.

A cutting-edge solution with global potential.